Octoplus will provide manufacturing and process development services and stands to earn $138 million in milestones. Biolex Therapeutics is paying OctoPlus $11 million for its 50% share of commercial ...

Biolex Therapeutics is calling it quits after burning through $190 million of venture cash from a slate of top-tier biopharma players on a once-promising hepatitis C drug. In its heyday the Pittsboro, ...

Duluth, Ga., and Pittsboro, N.C. - Biolex Therapeutics, Inc and Merial Ltd today announced that they have entered into a new, broad-ranging research and development collaboration to produce innovative ...

PITTSBORO, NORTH CAROLINA, November 28, 2006 - Biolex Therapeutics today announced results published in Nature Biotechnology demonstrating the ability of its proprietary LEX SystemSM to produce ...

Biolex Therapeutics Inc.’s $38 million bankruptcy includes millions of dollars owed to Triangle-area creditors, according to the company’s liquidation filing. That includes nearly $5 million owed to ...

Biolex Therapeutics has announced three new additions to its management team. Each of these pharmaceutical executives brings a proven track record in the development and commercialization of ...

PITTSBORO - Weeks after withdrawing plans for an initial public offering, Biolex is eyeing what is likely to be a temporary slowdown of its ambitious plans to put three drug candidates through human ...

Biolex Therapeutics, Inc. announced that the results from its United States Phase 2a clinical trial (the "PLUS" trial) of Locteron® will be presented today at the 44th Annual Meeting of the European ...

PITTSBORO, N.C. – Venture-backed Biolex Therapeutics has landed $36 million in Series B financing led by Polaris Venture Partners. The protein therapeutics company says that proceeds from the ...

Biolex Therapeutics, a Pittsboro, N.C.-based drug company whose lead candidate focuses on hepatitis C, has raised $30 million in Series C funding. Investor Growth Capital led the deal, and was joined ...